Institutional investors control 35.16% of the outstanding shares in CASC. This represents a greater percentage of ownership than at almost any other company in the Biotechnology industry. Additionally, during the quarter ended September 2016, these large investors purchased a net $3.2 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BVF PARTNERS LP Bought 2.9 Million shares of Cascadian Therapeutics In...